Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 212

1.

Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials.

Ciraulo DA, Hitzemann RJ, Somoza E, Knapp CM, Rotrosen J, Sarid-Segal O, Ciraulo AM, Greenblatt DJ, Chiang CN.

J Clin Pharmacol. 2006 Feb;46(2):179-92.

PMID:
16432270
2.

Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality.

Harris DS, Mendelson JE, Lin ET, Upton RA, Jones RT.

Clin Pharmacokinet. 2004;43(5):329-40.

PMID:
15080765
3.

Pharmacokinetics of the combination tablet of buprenorphine and naloxone.

Chiang CN, Hawks RL.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S39-47. Review.

PMID:
12738349
4.

Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naïve healthy male volunteers under a naltrexone block.

McAleer SD, Mills RJ, Polack T, Hussain T, Rolan PE, Gibbs AD, Mullins FG, Hussein Z.

Drug Alcohol Depend. 2003 Oct 24;72(1):75-83.

PMID:
14563545
5.

Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine.

Harris DS, Jones RT, Welm S, Upton RA, Lin E, Mendelson J.

Drug Alcohol Depend. 2000 Dec 22;61(1):85-94.

PMID:
11064186
6.

Effects of high-dose intravenous buprenorphine in experienced opioid abusers.

Umbricht A, Huestis MA, Cone EJ, Preston KL.

J Clin Psychopharmacol. 2004 Oct;24(5):479-87.

PMID:
15349002
7.

The pharmacodynamic and pharmacokinetic profile of intranasal crushed buprenorphine and buprenorphine/naloxone tablets in opioid abusers.

Middleton LS, Nuzzo PA, Lofwall MR, Moody DE, Walsh SL.

Addiction. 2011 Aug;106(8):1460-73. doi: 10.1111/j.1360-0443.2011.03424.x.

8.

Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.

Compton P, Ling W, Moody D, Chiang N.

Drug Alcohol Depend. 2006 Mar 15;82(1):25-31.

PMID:
16144748
9.

Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?

Mendelson J, Jones RT.

Drug Alcohol Depend. 2003 May 21;70(2 Suppl):S29-37. Review.

PMID:
12738348
10.

Effects of buprenorphine versus buprenorphine/naloxone tablets in non-dependent opioid abusers.

Strain EC, Stoller K, Walsh SL, Bigelow GE.

Psychopharmacology (Berl). 2000 Mar;148(4):374-83.

PMID:
10928310
11.

Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans.

Comer SD, Collins ED, Fischman MW.

Psychopharmacology (Berl). 2001 Feb;154(1):28-37.

PMID:
11292003
12.

Effects of buprenorphine/naloxone in opioid-dependent humans.

Stoller KB, Bigelow GE, Walsh SL, Strain EC.

Psychopharmacology (Berl). 2001 Mar;154(3):230-42.

PMID:
11351930
13.

Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms.

Chawarski MC, Moody DE, Pakes J, O'Connor PG, Schottenfeld RS.

J Subst Abuse Treat. 2005 Dec;29(4):307-12.

PMID:
16311183
14.

Enhanced buprenorphine analgesia with the addition of ultra-low-dose naloxone in healthy subjects.

La Vincente SF, White JM, Somogyi AA, Bochner F, Chapleo CB.

Clin Pharmacol Ther. 2008 Jan;83(1):144-52.

PMID:
17568402
15.
16.

Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations.

Nath RP, Upton RA, Everhart ET, Cheung P, Shwonek P, Jones RT, Mendelson JE.

J Clin Pharmacol. 1999 Jun;39(6):619-23.

PMID:
10354966
17.

Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers.

Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP.

Psychopharmacology (Berl). 1999 Jan;141(1):37-46.

PMID:
9952063
18.

Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.

Smith K, Hopp M, Mundin G, Leyendecker P, Bailey P, Grothe B, Uhl R, Reimer K.

Clin Ther. 2008 Nov;30(11):2051-68. doi: 10.1016/j.clinthera.2008.11.008.

PMID:
19108793
19.

Buprenorphine and naloxone interactions in methadone maintenance patients.

Mendelson J, Jones RT, Welm S, Brown J, Batki SL.

Biol Psychiatry. 1997 Jun 1;41(11):1095-101.

PMID:
9146820
20.

Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence.

Orman JS, Keating GM.

Drugs. 2009;69(5):577-607. doi: 10.2165/00003495-200969050-00006. Review.

PMID:
19368419
Items per page

Supplemental Content

Support Center